版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
ContainsNonbindingRecommendations
i
TableofContents
I.INTRODUCTION 1
II.BACKGROUND 2
III.GENERALCONSIDERATIONSFORCARTCELLDESIGNAND
DEVELOPMENT 3
A.CARConstruct 3
B.Vector 3
C.CellularStartingMaterial 4
D.FreshorCryopreservedFinalProducts 5
IV.CMCRECOMMENDATIONS 5
A.VectorManufacturingandTesting 6
B.Collection,Handling,andTestingofCellularStartingMaterial 7
C.CARTCellManufacturingandTesting 8
1.CARTcellmanufacturingprocesscontrol 9
2.CARTcellanalyticaltesting 11
3.LabelingforCARTcells 15
D.ManagingManufacturingChangesandAssessingComparabilityDuringthe
CARTCellProductLifecycle 16
1.Changemanagement 17
2.Comparabilitystudydesign 18
E.Single-SiteorMultisiteCARTCellManufacturing 19
1.Single-sitemanufacturing 19
2.Multisitemanufacturing 19
3.Multisitetesting 20
V.NONCLINICALRECOMENDATIONS 20
A.NonclinicalConsiderationsfortheCARConstruct 20
B.NonclinicalConsiderationsfortheCellularComponentofCARTCells 22
C.InVivoTestingofCARTCells 22
D.CARTCellswithAdditionalModifications 23
VI.CLINICALRECOMMENDATIONS 24
A.StudyPopulation 24
1.Advancedvs.earlydiseasestage 24
2.Tissue-agnosticapproach 24
3.Targetidentification 25
4.Pediatricsubjects 25
B.TreatmentPlan 26
1.Doseselection,startingdose,anddoseescalation 26
2.Repeatdosing 27
3.Staggering 27
4.Considerationformanufacturingdelayorfailure 27
ii
5.Bridgingtherapy 28
C.ClinicalPharmacologyConsiderations 28
1.Pharmacokinetics 29
2.Pharmacodynamics 29
3.Immunogenicity 30
D.SafetyEvaluationandMonitoring 30
1.Clinicalmonitoring 30
2.Toxicitygrading 31
3.Dose-limitingtoxicities(DLTs),stoppingrulesandattribution 31
E.CARTCellPersistenceandLongTermFollow-up 32
F.AllogeneicCARTCells 33
VII.REFERENCES 34
ContainsNonbindingRecommendations
ConsiderationsfortheDevelopmentofChimericAntigenReceptor(CAR)TCellProducts
GuidanceforIndustry
ThisguidancerepresentsthecurrentthinkingoftheFoodandDrugAdministration(FDAor
Agency)onthistopic.ItdoesnotestablishanyrightsforanypersonandisnotbindingonFDAorthepublic.Youcanuseanalternativeapproachifitsatisfiestherequirementsofthe
applicablestatutesandregulations.Todiscussanalternativeapproach,contacttheFDAstaff
responsibleforthisguidanceaslistedonthetitlepage.
I.INTRODUCTION
Chimericantigenreceptor(CAR)Tcellproductsarehumangenetherapy
1
productsinwhichtheTcellspecificityisgeneticallymodifiedtoenablerecognitionofadesiredtargetantigenfor
therapeuticpurposes.Thisguidanceisintendedtoassistsponsors,includingindustryand
academicsponsors,developingexvivo-manufacturedCARTcellproducts.Inthisguidance,
we,FDA,provideCARTcell-specificrecommendationsregardingchemistry,manufacturing,andcontrol(CMC),pharmacologyandtoxicology,anddesignofclinicalstudiesforoncologyindications(includinghematologicmalignanciesandsolidtumors).RecommendationsspecifictoautologousorallogeneicCARTcellproductsarenotedinthisguidance.ThisguidancealsoprovidesrecommendationsforanalyticalcomparabilitystudiesforCARTcellproducts.WhilethisguidancespecificallyfocusesonCARTcellproducts,someoftheinformationand
recommendationsprovidedmayalsobeapplicabletoothergeneticallymodifiedlymphocyte
products,suchasCARNaturalKiller(NK)cellsorTcellreceptor(TCR)-modifiedTcells.
Theserelatedproducttypescanbehighlyspecialized,andinmanycases,considerationsbeyondthoserecommendedinthisguidancewoulddependonthespecificproductandmanufacturing
process.Todiscussconsiderationsspecifictotheserelatedproductsornon-oncology
indications,werecommendsponsorscommunicatewiththeOfficeofTherapeuticProducts
(OTP)intheCenterforBiologicsEvaluationandResearch(CBER)beforesubmittingan
InvestigationalNewDrugApplication(IND)(e.g.,byrequestingapre-INDmeeting(Ref.1)).
1Humangenetherapyseekstomodifyormanipulatetheexpressionofageneortoalterthebiologicalpropertiesoflivingcellsfortherapeuticuse.FDAgenerallyconsidershumangenetherapyproductstoincludeallproductsthatmediatetheireffectsbytranscriptionortranslationoftransferredgeneticmaterial,orbyspecificallyalteringhost
(human)geneticsequences.Someexamplesofgenetherapyproductsincludenucleicacids,geneticallymodified
microorganisms(e.g.,viruses,bacteria,fungi),engineeredsite-specificnucleasesusedforhumangenomeediting,andexvivogeneticallymodifiedhumancells.Genetherapyproductsmeetthedefinitionof“biologicalproduct”insection351(i)ofthePublicHealthService(PHS)Act(42U.S.C.262(i))whensuchproductsareapplicabletotheprevention,treatment,orcureofadiseaseorconditionofhumanbeings(seeFederalRegisterNotice:ApplicationofCurrentStatutoryAuthoritiestoHumanSomaticCellTherapyProductsandGeneTherapyProducts(58FR
53248,October14,1993),
/media/76647/download)
.
1
ContainsNonbindingRecommendations
2
Ingeneral,FDA’sguidancedocuments,includingthisguidance,donotestablishlegally
enforceableresponsibilities.Instead,guidancesdescribetheAgency’scurrentthinkingonatopicandshouldbeviewedonlyasrecommendations,unlessspecificregulatoryorstatutory
requirementsarecited.TheuseofthewordshouldinAgencyguidancemeansthatsomethingis
suggestedorrecommended,butnotrequired.
II.BACKGROUND
CARTcells
2
aregenetherapy(GT)productsthatareregulatedunderFDA’sexistingframeworkforbiologicalproducts.Werecognizethatthedevelopment,manufacture,testing,andclinical
assessmentofCARTcellsischallenging.CarefuldesignandappropriatetestingoftheCARtransgene
3
anddeliveryvectorarecriticaltoproductsafety,specificity,andfunction.CARTcellmanufacturinginvolvesmultiplebiologicalmaterialsandcomplexmulti-stepprocedures,whicharepotentialsourcesofvariabilityamongproductlots.Thus,controlofthe
manufacturingprocessandappropriatein-processandlotreleasetestingarecrucialtoensure
CARTcellsafety,quality,andlot-to-lotconsistency.Inaddition,changestothemanufacturingprocessarecommonduringproductdevelopment.Itisessentialtounderstandtheeffectsofsuchchangesonproductquality.Comprehensiveproductcharacterizationstudiesarevaluablefor
identifyingrelevantcriticalqualityattributes(CQAs)thatcanbeassessedduringmanufacture,atlotrelease,andincomparabilityandstabilitystudiestoassuresafetyandefficacy(Ref.2).
Criticalprocessparameters(CPPs)canthenbeestablishedthroughprocessqualification,toensureconsistentCQAsforeverymanufacturedbatch.(Ref.2).FDA’sguidanceentitled“Chemistry,Manufacturing,andControl(CMC)InformationforHumanGeneTherapy
InvestigationalNewDrugApplications(INDs):GuidanceforIndustry,”January2020(Ref.3)(hereinafterreferredtoasthe“GTCMCGuidance”)describesthegeneralconsiderationsforGTproductmanufacturingandtesting.
NonclinicalevaluationofCARTcellsisnecessarytosupportaconclusionthatitisreasonablysafetoadministertheproductinaclinicalinvestigation(Title21oftheCodeofFederal
Regulations312.23(a)(8)(21CFR312.23(a)(8)).NonclinicaltestingofCARTcellscanbe
challengingduetotheinherentbiologicalcomplexityandvariabilityofthisproducttypeandthelimitedavailabilityofsuitableanimalmodelstotestsafetyandactivity.Acase-by-case
nonclinicaltestingstrategyshouldbeappliedusinginvitro,insilico,andinvivotesting
strategies,asappropriate,inconjunctionwithavailablenonclinicalandclinicaldatafromrelatedproductstosupportuseofCARTcellsinaproposedclinicaltrial.
Well-designedearly-phaseclinicalstudiesarecriticaltoestablishsafetyoftheproduct,adequacyofriskmitigationmeasures,dose-responserelationship,differencesinoptimaldosebasedon
differencesinindication,preliminaryevidenceofefficacy,andfeasibilityofmanufacturing.ForautologousCARTcells,early-phasestudiesalsoprovideinformationonhowlongitwilltaketomanufacturetheproductandwhetherbridgingtherapywillorwillnotbeusedasanattemptto
2CARTcellproductswillbereferredtoasCARTcellsthroughoutthisguidance.
3Forthepurposesofthisguidance,transgenemeansanexogenousgenethatisintroducedintoahostcell.Seealso(Ref.10).
ContainsNonbindingRecommendations
3
controltheactivediseasewhilesubjectswaitfortheCARTcelltreatment.ForallogeneicCARTcells,early-phasestudiescanbeinformativewithregardstotherisksofgraftversushost
disease(GVHD).Informationgainedfromtheseearly-phasestudiessupportthedevelopmentofCARTcellsinlater-phaseclinicalstudiesandmayexpeditetheclinicaldevelopmentofCARTcells.
III.GENERALCONSIDERATIONSFORCARTCELLDESIGNAND
DEVELOPMENT
CARTcellsarecomplexproductsthatmayincorporatemultiplefunctionalelements.The
natureofthesefunctionalelements,howthefunctionalelementsareintroducedintothecells
(i.e.,vectortype),thecellularstartingmaterial,andthefinaldrugproductformulationareallcriticaltoproductsafety,specificity,andfunction.Here,webrieflyoutlinekeyconsiderationsforCARTcelldesignanddevelopment.
A.CARConstruct
CARsgenerallycontaintwotypesofdomains:antigenrecognitionandsignaling.
AntigenrecognitiondomainsallowCARTcellstobindtooneormoretargetantigen(s).Werecommendsponsorsassesstheabilityofeachantigenrecognitiondomainto
specificallybindtoitstargetantigen,asdescribedinsectionV.Bofthisguidance.
Manyantigenrecognitiondomainsarederivedfrommurinemonoclonalantibodiesthatmaybeimmunogenicinhumans,leadingtorejectionoftheCARTcellsorothersafetyrisks(e.g.,anaphylaxis).Ifapproachestoreduceimmunogenicity(e.g.,“humanization”byComplementarity-DeterminingRegiongrafting)areused,werecommendtheIND
describethesechangesandtheirimpactontargetbindingandbiologicalactivity(Refs.4,5,6).WhenmultipleCARsareexpressedinasingledrugproduct,theCARconstructdesignshouldreducetheriskofrecombinationevents,iffeasible.
SignalingdomainsinitiateTcellactivation.Werecommendthatthefunctionalityofsignalingdomainsbewellsupportedbyinformationfrompreviousnonclinicaland
clinicalexperienceorthoroughlydemonstrated,asdescribedinsectionV.Bofthis
guidance.Forexample,thecontributionoftransmembranedomain,hinge,andlinkerregionsusedtoseparatedifferentfunctionalregionsoftheconstructshouldbe
evaluated,asthesemayaffectCARTcellspecificity,persistence,andactivity(Refs.7,8,9).
B.Vector
A“vector”isavehicleconsistingof,orderivedfrom,biologicalmaterialthatisdesignedtodelivergeneticmaterial.Examplesofvectorsincludeplasmids,viruses,andbacteriathathavebeenmodifiedtotransfergeneticmaterial(Ref.10).ForCARTcells,the
vectorisacriticalcomponentthatfurnishesapharmacologicalactivityforthetreatmentofdisease(sectionIV.BoftheGTCMCGuidance(Ref.3)).VectorsthatintegrateintocellularDNA(e.g.,retroviral-basedvectorsortransposons)canprovidelongterm
ContainsNonbindingRecommendations
4
transgeneexpressioncomparedtonon-integratingvectors.Longtermfollowupis
recommendedforproductsthatincludeintegratingvectors,becauseintegratingvectorsmayincreasetheriskofdelayedadverseevents(Ref.10).Thepredictedriskofdelayedadverseeventsisthoughttobelowfornon-integratingvectors,andgenerallylongtermfollowupwouldnotbeneeded.
InadditiontotheCAR,vectorsmayexpressadditionalfunctionalelements.For
example,vectorsmayexpressadditionalfunctionalelementsthatallowfortheselectionorenrichmentofcellularsubsetsduringmanufacturing(Ref.11);thatmodifyTcell
persistenceand/oractivity(Ref.11);orthatallowselectiveinvivoablation(“suicidegenes”)ofCARTcells(Refs.12,13,14).
ItshouldbenotedthateachadditionalfunctionalelementmayaffectCARTcellsafetyandeffectiveness.Werecommendsponsorsprovidejustificationandrelevantdatatosupportincorporationofadditionalelements.Thejustificationshouldincludean
assessmentofanyimpactthattheseadditionalelementswillhaveonCARTcell
specificity,functionality,immunogenicity,orsafety(seesectionV.Eofthisguidance).
Transgenesequencesthatareunnecessaryforthebiologicalfunctionofaproductmay
beimmunogenicinvivoorhaveotherunanticipatedeffectsonproductpersistenceor
activity.Asageneralguidingprinciple,werecommendthatunnecessarytransgenes
(e.g.,antibioticresistancegenesusedforplasmidselection)shouldnotbeincludedinthevector.
C.CellularStartingMaterial
ThestartingmaterialforCARTcellmanufactureisgenerallyobtainedbyleukapheresisofpatients(forautologousproducts)orhealthydonors(forallogeneicproducts).Safetyandregulatoryconsiderationsdifferforautologousandallogeneicproducts,asoutlinedinsectionIV.Bofthisguidance.
4
ParticularconsiderationshouldbegiventopatientswhohavereceivedCARTcells
previously.SuchpatientsmaybeconsideredfordifferentCARTcellclinicalstudiesduetolackofresponsetothepreviouslyadministeredCARTcells,relapseofthesame
condition,ortreatmentforadifferentmalignancy.CARTcellsmanufacturedusingcellularstartingmaterial(e.g.,leukapheresis)frompatientswhohavereceivedCART
cellspreviouslymaydifferfromthesametypeofCARTcellsmanufacturedusing
cellularstartingmaterialfrompatientswhohavenot.PreviouslyadministeredCART
cellsinthestartingmaterialmayhaveunexpectedeffectsonCARTcellmanufacturing(e.g.,expansionortransductionrates),potency,invivoexpansion,safety,andefficacy.
Therefore,evaluationofthepreviouslyadministeredCARTcelllevelsinthecellular
startingmaterialmaybeappropriate.ThismaybeaccomplishedbydetectionofcommonvectororCARfeaturestoevaluatethepresenceofpreviouslyadministeredCARTcells.Inaddition,werecommendyoucollectretentionsamplesofleukapheresismaterialinthe
4SeealsoFDA’sguidanceentitled“HumanGeneTherapyProductsIncorporatingHumanGenomeEditing:GuidanceforIndustry,”January2024(GEGuidance)(Ref.15).
ContainsNonbindingRecommendations
5
eventthatadditionalanalysisisnecessary.IfanautologousCARTcellclinicalstudy
willenrollpatientswhohavereceivedCARTcellspreviouslyandpatientswhohavenot,thepotentialdifferencesintheCARTcellsshouldbeevaluatedandconsideredinthe
clinicalstudydesignandanalysis.Werecommendsponsorsdiscusstheseconsiderationsforproductcharacterization,testing,dosing,andclinicalstudydesignwithOTPpriortotheINDsubmissionaspartofapre-INDmeeting(Ref.1).
D.FreshorCryopreservedFinalProducts
CARTcellsmaybeformulatedforfreshinfusionorcryopreservedforlater
administration.Thechoiceofformulationdependsontheproductdevelopmentstrategyandpracticalconstraints.
FreshCARTcellshavealimitedshelflifebeforeproductqualitydegrades.We
recommendthatthemaximumtimebetweenformulationandinfusionbedefinedandsupportedbystabilitystudiesandincludeconsiderationsforpreparationpriorto
administration.Additionally,thetimeframeinwhichreleasetestscanbeperformedis
limited.Therefore,itiscrucialtodevelopandimplementwell-designedlogistics,whichmayinclude:timingforsamplingandtestingforlotrelease;reportingQualityControl(QC)testingresultsandQualityAssurance(QA)reviewforlotrelease;scheduling
productshipping;andreceivingandhandlingofthefreshproductattheclinicalsite.
Ontheotherhand,cryopreservationallowssufficienttimeforfullreleasetestingand
flexibilityinschedulingpatientsforinfusion.WegenerallyrecommendcryopreservationwhenCARTcellsaremanufacturedatacentrallocationandshippedtoclinicalsitesforadministration.ForcryopreservedCARTcells,therisksassociatedwithinfusionofthecryoprotectantshouldbeassessed,andcontrolledthawingoftheproductattheclinical
sitemaybecriticaltomaintainproductquality.
Regardlessoftheformulation,thereshouldbeappropriateprocedurestoensureadequatecontroloftheCARTcellsduringshippingtotheclinicalsite.TheseproceduresshouldbedescribedintheINDandinplacebeforeinitiatingclinicalstudies.TheprocedurestoensureCARTcellproductqualityduringshipping,receipt,storage,andpreparationforinfusionshouldbevalidatedpriortolicensure.
IV.CMCRECOMMENDATIONS
ThissectionoftheguidanceaddressesconsiderationsspecifictoCARTcellproductsandisnot
designedtobeastand-aloneCMCguidance.PleaserefertothegeneralCMCguidancedocumentsoncellandgenetherapiesavailablefromFDA’swebsite:
/vaccines-blood-biologics/biologics-guidances/cellular-gene-therapy-
guidances.
WerecommendsponsorsorganizeinformationintheCommonTechnicalDocument(CTD)
formatwiththevectorCMCinformationdescribedinacompleteDrugSubstance(DS)section
ContainsNonbindingRecommendations
6
andtheCARTcellinformationorganizedintoaseparateDSsectionandaseparateDrug
Product(DP)section,asdiscussedinsectionIV.BoftheGTCMCGuidance(Ref.3).When
CARTcellsaremanufacturedusingacontinuousprocesswherethereisnocleardivision
betweentheDSandDP,werecommendthatyouprovideanexplanationtosupportyourDS/DPdistinctioninthesummaryinformationinModule2oftheCTDsubmission.TheCTDDS
sectionsshouldfollowtheformatandnumberingschemerecommendedinModule3ofFDA’sGuidanceforIndustry:“M4Q:TheCTD–Quality,”August2001(Ref.16),andthesectionsshouldbedistinguishedfromoneanotherbyincludingtheDSnameandmanufacturerinthe
heading(e.g.,section3.2.S.1GeneralInformation[name,manufacturer]).
TheemphasisforCMCinallphasesofdevelopmentisproductsafetyandmanufacturing
control.WerecommendthatCARTcellsbedevelopedfollowingalifecycleapproachwhereinformationisgatheredoverthecourseofproductdevelopmentandsubmittedinastage-
appropriatemanner.TheamountofCMCinformationtobesubmittedinyourINDdependsonthephaseandthescopeoftheclinicalinvestigationproposed(21CFR312.23(a)(7)).Therefore,youmaynotneedtocompleteallCTDsectionsinyouroriginalINDsubmission.Similarly,
manufacturingmustcomplywithCurrentGoodManufacturingPractice(CGMP),asappropriate
forthestageofdevelopment(section501(a)(2)(B)oftheFederalFood,Drug,andCosmeticAct(FD&CAct)(21U.S.C.351(a)(2)(B))(seealsoRef.17,and21CFR210.2).AdditionalCMC
informationmaybeneededtoalignproductdevelopmentwiththeclinicaldevelopment,
especiallywhenthelatterisrapidlyprogressingunderanexpediteddevelopmentprogram.Forexample,analyticalassaysshouldbefitforpurposetosupportearlyphasestudiesandqualified
beforeinitiatingclinicalstudiesthatareintendedtoprovidetheprimaryevidenceofeffectivenesstosupportamarketingapplication.
ForCARTcellsintheearlystagesofclinicaldevelopment,veryfewspecificationsare
finalized,andsometestsmaystillbeunderdevelopment(sectionV.A.4.aoftheGTCMCGuidance(Ref.3)).Characterizationdatacollectedduringearlystudiescaninformreleasecriteriausedinlaterdevelopmenttoensureproductandprocessconsistency.Thus,
characterizationstudiesarecrucialtosupportproductdevelopmentandcomparability
assessments.Forstudiesinwhichaprimaryobjectiveistogathermeaningfuldataaboutproduct
efficacy,werecommendthatacceptancecriteriaberefinedtoensurebatchesarewell-definedandconsistentlymanufactured.IntheBiologicsLicenseApplication(BLA),theproposed
commerciallotreleasecriteriashouldbebasedondatafromproductlotsshowntobesafeandeffectiveinclinicalstudies.
A.VectorManufacturingandTesting
TheGTCMCGuidance(Ref.3)providesrecommendationsformanufacturingand
testingofthevector.Thevectorsafetyandqualityshouldbesufficientlycharacterizedpriortoinitiationofclinicalstudies.Forlaterphasestudiesandforlicensure,thevector
mustbemanufacturedaccordingtoCGMPundersection501(a)(2)(B)oftheFD&CAct,andanalyticalassaysshouldbevalidated.(Ref.18).DuringCARTcellBLAreview,
vectormanufacturingfacilitiesaresubjecttoinspection.
ContainsNonbindingRecommendations
7
VectorqualitydirectlycontributestothequalityandconsistencyoftheCARTcells.Werecommendthatsponsorsdescribethevectorstructure,characterizationandtestingoftheMasterandWorkingCellBanks,characterizationofreferencematerials,andvector
manufactureandtesting.WealsorecommendstabilitystudiesforvectorsbeconductedtosupportholdandstoragetimesasdescribedinsectionV.A.7oftheGTCMCguidance(Ref.3).Vectorlotreleasetestingshouldincludemeasuresofsafety,identity,purity,
andbiologicalactivity.Anassaythatassessesthebiologicalactivityofthetransgene
maybedevelopedincoordinationwiththeCARTcellpotencyassay(seesectionIV.C.2ofthisguidance).Transgeneexpressionaloneasameasureofbiologicalactivitymaybesufficienttosupportearly-phaseINDstudies;however,additionalmeasuresofbiologicalactivitywilllikelyberequestedforclinicalstudy(s)intendedtoprovideprimaryevidenceofeffectivenesstosupportamarketingapplication.Additionally,werecommendthat
vectorstrengthbedeterminedduringlotreleasetestingtonormalizetheamountofvectorusedfortransductionduringCARTcellmanufacturing.Forexample,werecommend
testingviralvectorsfortransducingunitspermilliliter(mL)inasuitablecelllineor
healthydonorcells.ThisallowsdeterminationoftheamountofvectorthatisaddedpercelltoachievethetargetpercentageofCAR-positivecellsintheCARTcellDPwhileensuringthatthevectorcopynumberremainswithintargetspecifications.
Vectorsafetytestingshouldincludemicrobiologicaltestingsuchassterility,
mycoplasma,endotoxin,andadventitiousagenttestingtoensurethattheCARTcellDPisnotcontaminated.Additionaltestingmayberecommendeddependingonthetypeof
transgenevectorbeingused.Forexample,thereareadditionalsafetyconcernsand
testingexpectationsrelatedtotheuseofretroviral-basedvectors(sectionV.A.4.b.iioftheGTCMCGuidance(Refs.3and19)).Therecommendationsforlongtermfollow-upofpatientsgenerallydependsonthesafetyconcernsassociatedwiththevectorandthe
propensityforthevectortointegrate(Ref.10).
B.Collection,Handling,andTestingofCellularStartingMaterial
Here,wedescribeconsiderationsforcellularstartingmaterial,usingstartingmaterialobtainedfromleukapheresis(referredtoas“leukapheresisstartingmaterial”)asan
example.Therecommendationsinthissectionmaybeapplicabletoothertypesof
cellularstartingmaterialaswell.TestingrecommendationsforcellbanksoriginatingfromallogeneiccellsortissuesarediscussedinsectionV.A.2.c.ii.boftheGTCMCGuidance(Ref.3).
Collectionoftheleukapheresisstartingmaterialshouldbeconductedinaccordancewiththeregulationsin21CFRpart1271.Autologousleukapheresisstartingmaterialdoesnotrequireadonoreligibilitydetermination(21CFR1271.90(a)(1)andRef.20),butyou
mayconsiderarisk-basedapproachforscreeningortesting(Ref.3).Allogeneic
leukapheresisstartingmaterial,ontheotherhand,doesrequireadonoreligibility
determination,includingscreeningandtestingforrelevantcommunicablediseaseagentsanddiseases(21CFRpart1271,SubpartC).
ContainsNonbindingRecommendations
8
Werecommendthatproceduresusedforhandlingtheleukapheresisstartingmaterial
fromcollectiontothestartofthemanufacturingprocessaredescribedintheINDas
discussedinsectionV.A.2.c.iioftheGTCMCGuidance(Ref.3).Thisdescription
shouldincludeanywashstepsorcryopreservationprocedures.Werecommendthese
procedures,includinghandlingofthecellsandshipmenttothemanufacturingsite,beinplaceatallleukapheresiscollectionsitestoensurequalityofthematerial.Youshould
haveappropriateproceduresinplacetoensureadequatecontroloftheleukapheresis
startingmaterialduringshippingtothemanufacturingfacility(e.g.,temperaturecontrol),andinformationregardingshippingcontainersandtemperaturemonitoringshouldbe
provided.Validationoftheshippingprocessandanyholdorcryopreservationsteps,
includingassessmentofleukapheresisstartingmaterialstabilityundertheintended
conditions,shouldbeincludedforlicensure.Oncetheleukapheresisstartingmaterialhasbeenreceivedbythemanufacturingfacility,subsequentmanufacturingmustcomplywithCGMPasappropriateforthestageofdevelopment(seeRef.17,and21CFR210.2).
Duetopatientordonorvariability,thecellularstartingmaterialcanrepresentamajor
sourceoflot-to-lotvariabilityinCARTcellqualityandfunction.Theprobabilityof
manufacturingsuccessmaybeincreasedbyestablishingacceptancecriteriaforthe
leukapheresisstartingmaterialusedinCARTcellmanufacturing,asexperienceis
gainedthroughoutproductdevelopment.Forexampl
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 塑料鞋行业技术创新趋势考核试卷
- 航空运动飞行器销售与租赁业务考核试卷
- 轻质建筑材料在社区活动中心设计的应用考核试卷
- 骨骼与人体运动苏教版四年级科学教材
- 水轮机发电站变压器选型考核试卷
- 人教版高一历史课程导航
- 掌握苏教版六下数学知识点轻松应对考试详解
- 小学数学口算三年级
- 人教版四年级科学创新实验教学
- 2023-2024学年陕西省西安市西北工大附中中考一模英语试题含答案
- 大庆市民政局所属事业单位招聘真题
- 国开2024年秋《机电控制工程基础》形考任务4答案
- 企业管理人员安全培训考试题带答案(模拟题)
- 2024年事业单位考试题库及答案(200题)
- 2024年部编版新教材语文小学一年级上册第二单元复习课教案及单元复习题(有答案)
- Unit 6 A day in the life Section A 1a-1e 教学设计 2024-2025学年人教版英语七年级上册
- Unit 1 第3课时 Grammar 课件译林版2024七年级英语上册
- 统编版2024道德与法治七年级上册 教材单元思考与行动解答示例
- 安全生产治本攻坚三年行动任务清单
- NBT 35080-2016 水电站气垫式调压室设计规范
- 《肾病综合征》PPT课件
评论
0/150
提交评论